KinomeScan

KinomeScan is a leading kinase profiling and screening platform that provides high-throughput, site-directed competition binding assays for drug discovery. Originally developed by Ambit Biosciences and now a core part of Eurofins Discovery, the platform enables the quantitative measurement of interactions between test compounds and a comprehensive panel of over 500 human kinases and clinically relevant mutants. The technology is widely used by pharmaceutical and biotechnology companies to assess compound potency, selectivity, and off-target liabilities. KinomeScan supports various modalities, including small molecules, peptides, and protein degraders, and has been instrumental in numerous IND filings and drug approvals.